| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Giovanni Alejandro Salgado Alvarez, Samanta Mayanin Pinto Galvez, Uriel Garcia Mora, Ana Delfina Cano Contreras, Cristina Durán Rosas, Bryan Adrián Priego-Parra, Arturo Triana Romero, Mercedes Amieva Balmori, Federico Roesch Dietlen, Sophia Eugenia Martinez Vazquez, Ines Osvely Mendez Guerrero, Luis Alberto Chi-Cervera, Raúl Bernal Reyes, Leonardo Alberto Martinez Roriguez, Maria Eugenia Icaza Chavez and Jose Maria Remes Troche |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ana Delfina Cano Contreras, MD, Attending Doctor, Doctor, Instituto de Investigaciones Médico Biológicas , Universidad Veracruzana, C. Agustín de Iturbide , Veracruz 91700, Veracruz, Mexico. anacano1403@gmail.com |
| Key Words |
Fatty liver; Cardiovascular risk; Hepatic steatosis; Fibrosis; Liver disease |
| Core Tip |
Metabolic-dysfunction-associated fatty liver disease (MAFLD) allows identification of metabolically complicated patients. Evaluation of the relationship between hepatic fibrosis and cardiovascular risk (CVR) in patients with MAFLD using the Framingham risk score allows us to identify which patients with MAFLD and liver fibrosis have a higher CVR than patients without fibrosis. |
| Publish Date |
2022-08-26 09:51 |
| Citation |
Salgado Alvarez GA, Pinto Galvez SM, Garcia Mora U, Cano Contreras AD, Durán Rosas C, Priego-Parra BA, Triana Romero A, Amieva Balmori M, Roesch Dietlen F, Martinez Vazquez SE, Mendez Guerrero IO, Chi-Cervera LA, Bernal Reyes R, Martinez Roriguez LA, Icaza Chavez ME, Remes Troche JM. Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic dysfunction-associated fatty liver disease. World J Hepatol 2022; 14(8): 1633-1642 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i8/1633.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i8.1633 |
